Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4
Evolent Health Inc Class A +8.58% Pre
Evolent Health Inc Class A EVH | 2.53 2.53 | +8.58% 0.00% Pre |
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:
EVH) with a Buy and lowers the price target from $6 to $4.
